This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining Structure Therapeutics' GLP-1 candidate GSBR-1290 and the results from its phase 1b clinical trial in type 2 diabetes.

Ticker(s): GPCR

Who's the expert?

Institution: University of Arkansas Medical Services Health

  • Director of the diabetes program at UAMS Health
  • Clinical interests include type 1 diabetes, type 2 diabetes, Diabetes management with exercise, insulin pumps, closed-look insulin pump systems, and continuous glucose monitoring systems
  • Manages about 600 patients with type 2 diabetes and is familiar with Brenzavvy via the published clinical trials

Interview Goal
to discuss the current standard of care and the potential of GSBR-1290, an oral GLP-1 receptor agonist being developed by Structure Therapeutics for weight loss and the treatment of type 2 diabetes.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.